Evaluation of the Efficacy and Safety of the Allurion® Gastric Balloon in 300 Patients from a Single Metabolic Center in Ecuador
Swallowable gastric balloons help Latin American patients lose 14% of body weight without surgery, filling a gap for underrepresented populations.
In 300 Ecuadorian patients with BMI ≥25, the Allurion® swallowable gastric balloon produced mean total weight loss of 14.4% at 12 months with acceptable safety (mostly minor adverse events). This adds real-world Latin American data for a non-surgical obesity intervention in a population underrepresented in prior trials.
What the study was
- Study design
- Retrospective cohort study
- Population
- 300 patients, median BMI 29.2 kg/m², Ecuador; aged ≥13 years
- Sample size
- 300
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Obes Surg
Why it surfaced
Real-world Latin American obesity device data. Moderate TWL (~14.4% at 12 months) in a region underrepresented in obesity intervention trials. Single-center retrospective design limits generalizability.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.